Australie - anglais - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - captopril -

Canada - anglais - Health Canada

bristol-myers squibb canada - captopril - tablet - 12.5mg - captopril 12.5mg - angiotensin-converting enzyme inhibitors

Canada - anglais - Health Canada

apotex inc - captopril - tablet - 12.5mg - captopril 12.5mg - angiotensin-converting enzyme inhibitors

États-Unis - anglais - NLM (National Library of Medicine)

mylan institutional inc. - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd) - captopril 12.5 mg - captopril tablets, usp are indicated for the treatment of hypertension. in using captopril tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see warnings). captopril tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. in patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. captopril tablets are effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. the beneficial effect of captopril in heart failure does n

États-Unis - anglais - NLM (National Library of Medicine)

sandoz inc. - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd) - captopril 12.5 mg - captopril tablets, usp are indicated for the treatment of hypertension. in using captopril tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see warnings). captopril tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. in patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. captopril tablets are effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. the beneficial effect of captopril in heart failure does not require the presence of dig

États-Unis - anglais - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd) - captopril 12.5 mg - captopril tablets are indicated for the treatment of hypertension. in using captopril tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see warnings). captopril tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. in patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. captopril tablets are effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. the beneficial effect of captopril in heart failure does not require the presence of digitali

États-Unis - anglais - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd) - captopril 12.5 mg - captopril tablets, usp are indicated for the treatment of hypertension. in using captopril tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see warnings ). captopril tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. in patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. captopril tablets are effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. captopril tablets, are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. the beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. captopril tablets, are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤ 40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. captopril tablets, are indicated for the treatment of diabetic nephropathy (proteinuria > 500 mg/day) in patients with type i insulin-dependent diabetes mellitus and retinopathy. captopril tablets, usp decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). in considering use of captopril tablets, it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. in addition, ace inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see warnings: head and neck angioedema  and intestinal angioedema ). captopril tablets are contraindicated in patients who are hypersensitive to this product or any other angiotensin-converting enzyme inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ace inhibitor). do not co-administer aliskiren with captopril tablets in patients with diabetes (see precautions, drug interactions ). captopril tablets are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer captopril tablets within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see precautions, drug interactions ).

États-Unis - anglais - NLM (National Library of Medicine)

american health packaging - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd) - captopril 12.5 mg - captopril tablets, usp are indicated for the treatment of hypertension. in using captopril tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see warnings ). captopril tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. in patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. captopril tablets are effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. the beneficial effect of captopril in heart failure does not require the presence of

États-Unis - anglais - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd) - captopril 12.5 mg - hypertension: captopril tablets us?are indicated for the teatment of hypertension. tn using captopril, conslderallon should be gtven to the risk of neutropenia!agranutocytosls (seewarnings). captoprll maybe used as initial therapy for patientswilh normal renal function, in whomthe rlskls relatively low. in patients with impaired renal function, particularly those wfth collagen vascular olseas6, captopril should be resened for,hypertenslves who have either developed unacceptable side effecls on otherdrugs, orhave failed to responq satislactorily 10drug combinations. captopril is effective alone and in combination with other antihypertensive agents, ~peclally thiazide-type diuretics. the blood pressure lowering effecls of captoprif and thlazldes are approximalaly a

Canada - anglais - Health Canada

ftp-pharmacal inc. - captopril - tablet - 12.5mg - captopril 12.5mg - angiotensin-converting enzyme inhibitors